ArticleDermatology reports2025
A rare vascular manifestation in chronic myeloid leukemia: a case report and literature review of Bier's spot development during nilotinib treatment.
Article in Dermatology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bier's spots are rare angiospastic macules often associated with physiologic vasoconstriction. This case report describes a 35-year-old man with chronic myeloid leukemia (CML) treated with nilotinib who developed Bier's spots, a previously unreported adverse effect of the drug. The patient presented with asymptomatic hypopigmented macules on the hands and legs that appeared during venous stasis and resolved with elevation. This case emphasizes the need to recognize potential vascular side effects of tyrosine kinase inhibitors (TKIs) and highlights Bier's spots as a benign but remarkable manifestation in patients undergoing nilotinib therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.